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The impact on the care of breast cancer patients, of a pharmacy technician-led medication review and counselling clinic, provided in
an outpatient setting, was investigated using a controlled randomised study. Compared to the controls, clinic patients showed a
significantly improved level of understanding of their chemotherapy support medication (95% CI for difference in mean knowledge
rating scores¼2.165–2.826, Po0.001) and a significant reduction in the median number of support items required (two compared
to five in the control, Po0.001). This resulted in a significant reduction in mean medication expenditure per patient (d26.70 vs
d10.20, 95% CI for the mean difference in cost d6.72–d26.26, Po0.001). The clinic was also associated with significant reductions in
chemotherapy delays (Po0.001) and dose reductions due to side effects (P¼0.003). Other benefits from the clinic were a reduction
in pharmacy dispensing time and a highly significant reduction in pharmacy time spent resolving post-clinic prescription queries
(Po0.001). Taking into account the initial technician training cost, the scheme represented an annual saving to the Trust of over
d15000. The clinic serves as a model for those wishing to improve outpatient services to breast cancer patients.
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It is widely accepted that a cornerstone of effective breast cancer
chemotherapy is to maximise the appropriate dose while mini-
mising the often unpleasant and debilitating side effects. A recent
study in women receiving chemotherapy in the first 12 months
after diagnosis for breast cancer showed that the incidence of
serious effects requiring emergency intervention in hospital (61%)
is likely to be higher than that predicted from clinical trial data
(Hassett et al, 2006). While support medication strategies have
improved over the years, it is not uncommon for patients to
become reluctant to continue with further cycles of treatment if
they have already experienced side effects from initial cycles of
chemotherapy (Craig and Powell, 1987; Atkins and Fallowfield,
2006). Chemotherapy support medication is co-prescribed with the
intention of minimising side effects with the hope that this will
improve chemotherapy concordance, which in turn will assist the
success of chemotherapy.
Research has indicated that cancer patients who concord with
oral chemotherapy regimens have a higher survival rate than those
who do not (Porzsolt et al, 1989; Spiegel, 1997).
Concordance can be described as a process of prescribing and
medicine taking in a prescriber – patient partnership (Stevenson,
2001). This is particularly important in situations like chemother-
apy support medication, where the patient must first recognise the
side effect of the chemotherapy, then select the correct drug and
self-administer the right dose for the correct period, remote from
her immediate healthcare team. All members in the healthcare
team have a responsibility to foster concordant relationships with
patients. Prescribing physicians may not be able to do this for a
variety of reasons (Stevenson et al, 2000). These include lack of
time to discuss individual medication issues such as potential side
effects (what to look out for and what to do about them) and
because the prescribing setting may not lend itself to effective
counselling.
Cancer patients face the challenges of understanding often
complex and protracted chemotherapy regimens, their side effects
and management, while at the same time coming to terms with a
potentially life-threatening diagnosis. Acceptance of treatment is
largely based on the reality of a terminal condition without it and
patient understanding of how chemotherapy can be made less
debilitating with support medication is fundamental to building a
concordant relationship.
Pharmacists and more recently, pharmacy technicians counsel
patients on their medications in a variety of settings as part of
routine clinical pharmacy practice. Patients may have good access
to staff on the ward where they receive their chemotherapy, but a
busy ward frequently is not conducive to effective information
transfer. Studies conducted by pharmacists in other disciplines,
such as anticoagulation (Radley and Hall, 1994; Boddy, 2001),
dermatology (Tucker, 2004) and palliative care (Austwick et al,
2002) which showed improved quality of care, patient under-
standing and use of resources, suggest that the outpatient clinic
may be a suitable alternative setting.
Like many breast cancer clinics, patients are seen at Worthing
Hospital under a shared care agreement with another local NHS
Trust. A co-ordinated, multi-disciplinary team approach relies
for its success on good communication between clinicians,
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schemotherapy nurses on the Medical Day Case Unit (MDCU) and
pharmacists and pharmacy technicians working in aseptic services.
Prior to this study, any pharmaceutical issues surrounding their
support medication could only be resolved post-clinic, when the
physician had departed. It was suggested that the service, which
was under increasing capacity pressures, could be improved by
direct pharmacy involvement at clinic level, when the patient and
all healthcare team members were present.
A pharmacy technician who has successfully completed an
accredited medicines management course is deemed to be
competent in routine medication review and drug history taking.
These are useful attributes when educating patients on their
chemotherapy support medication and assessing their ability to
cope with this. This then frees the pharmacist to deal with more
complex pharmaceutical care issues raised by the latter, such as
drug interactions and side effects, thus making best use of
pharmacy resources.
As a result, a pharmacy technician-led outpatient clinic for
breast cancer patients being treated on MDCU at Worthing
Hospital was proposed. This was considered a potentially useful
setting in which to perform a complete medication review and
research its effect, through a controlled study on a range of
features of patient care.
METHODS
Approval for the study including all data collection forms and
methods, was obtained from the West Sussex Local Research
Ethics Committee (04/Q1911/45) and the Sussex NHS Research
Consortium (0457/WASH/2004) on 23/11/04 and 6/1/05 respec-
tively, prior to commencement of the study.
Technician training and accreditation
The research technician (BR) underwent the South East Medicines
Management Education and Development Team’s accredited
medicines management course. The course consists of private
study, supplemented with study days and is assessed by
demonstration of competence in work-based activities in a written
portfolio and observed structured clinical examination. This
provided a knowledge and skills framework that was supplemented
by additional directed study on patient counselling, chemotherapy
regimens for breast cancer and relevant support medication,
identification of side effects and drug interactions. Assessment
of the pharmacy technician’s knowledge of chemotherapy support
medication was conducted by formal written examination.
Assessment of the technician’s counselling skills was undertaken
by in-practice observation following completion of a Trust in-
house counselling course.
All assessment and training was undertaken during one year
(February 2004 to January 2005). Following assessment, the
technician was established within the outpatient clinic in a
dedicated consulting office. Approval for this was obtained from
the consultant oncologist treating breast cancer patents at
Worthing Hospital and the senior nursing staff on MDCU and in
the Outpatient Department.
Study design
The research took the form of a randomised, controlled study,
outlined in Figure 1. The project lasted 12 months including a 1-
week pilot study consisting of ten patients to assess applicability of
procedures and data collection forms. The pilot indicated that no
appreciable changes to protocol or data collection procedures were
required and the ten pilot patients were included in the overall
analysis.
Patient recruitment
Patients with a diagnosis of breast cancer and on course 2, 3 or 4 of
their chemotherapy, as identified from their records, were
approached by the chief investigator (HR) on attending MDCU.
Each patient was provided with verbal and written information
about the research and asked to provide written consent. Patients
receiving treatment for either adjuvant or metastatic disease
receiving a variety of regimens, were included. Patients under 18
years old were excluded.
Consenting participants were informed that on their next MDCU
visit, they would be asked a series of questions testing their
understanding of their support medication.
Patient randomisation
Patients were randomised to either the control arm, where they
received conventional care, including routine ward counselling
from a nurse on the use of their support medication prior to
discharge, or to the experimental arm where they attended the
pharmacy technician-led outpatient clinic. Randomisation was by
a computer-generated random number table produced in Micro-
soft Excel. Each patient received an information sheet explaining
which study arm they had been allocated to and what this involved.
Patient assessment at follow-up
Patients were interviewed by the chief investigator at their next
outpatient appointment after a further chemotherapy cycle
(usually of 3 weeks’ duration) had been completed.
Control arm
Prior to their next visit, subjects were sent a letter inviting them
to arrive early at the clinic and to bring a copy of their GP repeat
medication list with them. At the clinic and prior to their
scheduled consultant appointment, they were also interviewed
about this list and any other medications they were taking in
addition to their chemotherapy. The information was used to
compile an accurate drug history and to highlight any potential
drug interactions with the patient’s chemotherapy or chemother-
apy support medication. Any problems so identified were
forwarded to the consultant to discuss with the patient when they
saw them at the allocated time.
The prescription for the patient’s next cycle of chemotherapy
resulting from the consultation was tracked via the pharmacy
aseptic department. Any issues that arose from this prescription
were resolved by that department’s personnel and recorded as part
of the study. This was primarily to document the time taken to
resolve prescription problems by contacting the consultant after
the clinic.
At their subsequent clinic appointment, patient understanding
of their support medication was re-assessed as at baseline.
Research arm
Patients were asked to attend the pharmacy technician-led
outpatient clinic prior to seeing the consultant oncologist at their
next outpatient appointment clinic. At the pharmacy technician-
led clinic, the following issues were recorded:
(1) A full drug history
(2) Potential drug interactions
(3) Whether supplies of support medications were required
(4) The patient’s perception of the clinic and whether they found
it beneficial or not.
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sInformation from items 2 and 3 was noted and attached to the
patient’s notes so that the consultant could make use of it when
consulting with the patient.
After the consultation, the resulting prescription was tracked as
in the control arm.
Patients were interviewed again by the chief investigator prior to
their next consultant appointment, to assess their knowledge of
support medication. As with the control arm, this took place after
two chemotherapy cycles had elapsed since enrolment. The chief
investigator remained unaware of which arm of the trial each
patient was in.
Primary outcome measure – baseline assessment of patient
understanding of support medication
The chief investigator (HR) interviewed each consented patient
using a standard question set, asking the patient to explain what
each of their support medications was for and how they used it.
Assessments were recorded as an overall rating of the subject’s
understanding on a Likert scale from 1¼very poor to 5¼very
good, plus a drug-specific score derived from marks awarded for
various pieces of information: drug name (þ2); indication (þ2);
dose frequency (þ2); dose duration (þ1); dose (þ1). Thus the
maximum score per drug was 8 and the minimum 0. The average
score per drug was also calculated. Assessments were conducted
prior to randomisation; the chief investigator was blind during
subsequent, post-randomisation assessments.
Secondary outcome measures
There were a number of secondary outcomes of interest. All
secondary outcome measures were compared between control and
clinic arms directly.
Patient selected for trial participation currently receiving 
chemotherapy treatment for breast cancer and on either course 
number two, three or four.
Patient consented to participation in trial.
At next patient attendance on MDCU for chemotherapy, baseline data 
collected for primary outcome by the chief investigator.
Patient randomised to either the control arm or research arm.
Control Arm 
1. Patient informed of randomisation outcome
2. Patient attended the outpatient department 
prior to consultant appointment time after one 
chemotherapy cycle and was interviewed by 
the chief investigator (interview 1). A drug 
history was obtained for the patient.
All forms were piloted for one week 
Pharmacy aseptic department notified the 
principal investigator if there were any 
problems arising from the patient’s 
chemotherapy prescription.
Research Arm 
1. Patient informed of randomisation outcome.
2. Patient attended pharmacy technician-led 
clinic prior to consultant appointment time 
after one chemotherapy cycle and was 
interviewed by the pharmacytechnician 
(interview 1).
All forms were piloted for one week 
Pharmacy technician recorded if there were 
any problems arising from the patient’s 
chemotherapy prescription that were 
resolved at the clinic.
Follow-up data collection for primary outcome.
Patient interviewed by the chief investigator (interview 2) at the next consultant outpatient 
appointment i.e.after the second chemotherapy cycle since enrolment. Interviews took 
place thirty minutes before the patient saw the consultantin outpatient department for both 
study arms.
Data collection for secondary outcomes.
Patient finished total number of courses of chemotherapy for that regimen.
Once sample size achieved for both study arms, patient recruitment stopped.
Figure 1 Overview of the research design.
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s(1) The numbers of patients experiencing delays in receiving their
chemotherapy.
(2) The numbers of patients requiring chemotherapy dose
reductions.
(3) Numbers of patients having potential drug interactions
between GP prescribed medication and chemotherapy or
chemotherapy support medication.
(4) The number of chemotherapy support medication items
supplied per patient.
(5) The average cost of chemotherapy support medication
supplied per patient.
(6) The numbers and costs of chemotherapy support medication
not supplied.
(7) The average amount of pharmacy time per patient spent
resolving medication issues.
(8) The numbers of patients requiring a prescription intervention
at the point of dispensing.
All medication costs were calculated using hospital prices
prevailing at the time of the study.
Data analysis
All statistical analyses were conducted using Minitab version 13
(Minitab Inc., State College, PA, USA), taking Po0.05 as an
acceptable level of probability indicating statistical significance.
For the primary outcome measure (patient knowledge score)
mean scores were compared before and after clinic attendance in
both the control and clinic arms using Student’s t-test.
For the secondary outcome measures, the proportions of
patients experiencing chemotherapy delays and reductions were
compared using the w
2 test.
The numbers of chemotherapy support medications supplied
for each patient were compared using the Mann–Whitney
U-test and the mean costs of items supplied were compared using
a two-sample t-test. The mean times spent resolving prescription
issues in the two study arms were compared using a two-sample
t-test.
RESULTS
All the chemotherapy regimens encountered in this study were
prescribed against standard proformas, used on a day to day basis
across the Sussex Cancer Network; these had been checked and
verified across the whole cancer network, and were last scrutinised
as part of the National Cancer Peer Review Programme in 2005/6.
Antiemetics were also prescribed according to the cancer network
guidelines on the prevention and treatment of nausea and
vomiting in adults receiving chemotherapy. The prescribing of
support medication was absolutely consistent across the two arms
of the trial as the same standard network chemotherapy proformas
were used.
Chemotherapy regimens varied between patients according to
disease stage and comorbidity. Patients were not stratified
during randomisation for the nature of the chemotherapy regimen
used or cycle of therapy. Actual regimens and cycle numbers for
control and clinic arms are shown in Table 1; there was a
significantly higher proportion of patients receiving adjuvant
therapy in the clinical arm compared to the control (P¼0.003,
w
2¼9.074). There were no differences in cycle numbers.
The imbalance between the two arms of the trial, in the numbers
of patients receiving trastuzumab monotherapy, is discussed
below.
One patient withdrew from each arm of the study, so the
base in each was reduced to 69. Key results are summarised in
Table 2.
Primary outcome: level of patient understanding about
support medication
There were no statistically significant differences between the
mean baseline scores in the control and clinic arms (P¼0.942) or
between second measurement and baseline in the control arm
(P¼0.822). In contrast, the difference from baseline in the clinic
arm was very highly significant (Po0.001).
Secondary outcome measures
Significantly fewer patients experienced chemotherapy delays after
attending the pharmacy technician-led clinic (P¼0.001) and
significantly fewer patients also experienced chemotherapy dose
reductions (P¼0.003).
Forty-seven (33.8%) of the 139 patients eligible for baseline
evaluation had potential drug interactions highlighted. The
difference between the control and clinic arms was not statistically
significant (P¼0.188); these data suggest that the pharmacy
technician-led clinic detected more potential drug interactions but
this hypothesis is unproven. Most drug interactions were between
GP prescribed medication and chemotherapy support medication
rather than the chemotherapy itself. The most common interac-
tions were between corticosteroids and non-steroidal anti-inflam-
matory drugs, antidiabetic agents, antiepileptic agents and
antihypertensive medication. In the majority of cases it was
accepted that a short course of corticosteroids would not lead to a
clinically significant interaction with these other agents; however,
it would be unwise to assume that this would be the case in all
patients where polypharmacy and comorbidities may mitigate.
There were significantly fewer chemotherapy support items
supplied per patient in the clinic arm compared to the control
(Po0.001); this cross-correlated with additional data from the
pharmacy technician-led clinic where the median number of items
not supplied was also three. The bulk of unnecessary prescribing
consisted of antiemetics and mouth care products; G-CSF was also
prescribed unnecessarily in a small number of patients. A pilot
study had shown that it took an average of 3.6min for a pharmacy
technician to dispense and a pharmacist to check an item of
chemotherapy support medication; this represented a time saving
Table 1 Nature of the chemotherapy regimes and treatment modes
used in the control and clinic arms of the study
Regimen
Control arm
(no. of patients)
Clinic arm
(no. of patients)
Adjuvant FEC 60mgm
 2 81 5
Adjuvant EC 60 6 5
Adjuvant paclitaxel 5 —
Adjuvant docetaxel — 2
Adjuvant FEC 75mgm
 2 17 26
Adjuvant AC — 1
Adjuvant EC 75 — 3
Neo-adjuvant FEC 75 1 2
Metastatic epirubicin+docetaxel 2 —
Metastatic docetaxel 10 10
Metastatic trastuzumab 13 2
Metastatic vinorelbine 3 2
Metastatic EC 60 3 —
Metastatic capecitabine 2 —
Metastatic docetaxel and trastuzumab — 2
Chemotherapy cycle number Control arm Clinic arm
25 3 5 3
31 5 1 3
42 4
A¼Adriamycin (doxorubicin); C¼cyclophosphamide; E¼epirubicin; F¼fluorouracil.
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sof approximately 10.8min per breast cancer patient in this study. If
the over-prescription at the first cycle was perpetuated over the full
five courses of therapy, then a total of 54min of pharmacy time
would be wasted. In terms of dispensary time saved, this would
amount to approximately 146h per annum.
There was a highly significant reduction in mean cost of items
supplied to control patients compared to clinic patients (t¼3.34,
point estimate for difference¼16.49, CI¼6.72–26.26, Po0.001).
Information collected in the research arm allowed calculation of a
mean cost of medication not supplied of d17.54 per patient. Again,
if over-prescription was perpetuated over five courses, this would
be a waste of d87.70 and projecting over a typical year involving
162 patients, a saving of d14207.40 could be made.
Technician time invested overall in the clinic amounted to 24.7h
per annum, costing d305.29 (based on current salary scales). This
input was calculated by subtracting the time saved not having to
resolve prescription-related problems post-clinic from the actual
time expended in the clinic. In addition, the technician time saved
by not dispensing unnecessary items was 146h per annum, costing
d1804.56. Therefore, the total time saved was 146–24.7¼121.3h
per annum, saving d1499.27.
The above savings should be set against the cost of the initial
technician training in medicines management (approximately
d1800); but this is a one-off investment paid for by the Strategic
Health Authority and a mandatory requirement of standard post-
qualification training for all pharmacy technicians in the Trust.
The additional costs incurred in preparing the technician for the
cancer clinic role were d155 – again a one-off investment.
The mean cost of items wasted from previous supplies returned
to the pharmacy by patients in the clinic arm of the study and
subsequently destroyed was d26.70. As an indication of unneces-
sary wastage this would amount to an annual saving of d4325.40,
based on the throughput of breast cancer patients at Worthing
Hospital. This is probably a minimum, as patients do not always
return unwanted or unused medicines to the pharmacy.
There was a highly significant reduction in the amount of
pharmacy time per patient spent resolving prescription issues
in the clinic arm compared to the control arm of this study
(t¼5.31, point estimate for the difference¼8.0, 95%CI¼5.05–
11.04, Po0.001); fewer patients required a prescription interven-
tion at the point of dispensing in the clinic arm compared to the
control arm (30 vs 45.7%) but the difference did not reach
statistical significance (df¼1, w
2¼3.439, P¼0.064); but together,
these results suggest that those interventions required in the clinic
patients were of a more complex nature.
DISCUSSION
The pharmacy technician-led clinic for breast cancer patients
could easily be developed for other cancer specialities where
routine chemotherapy support medications are used. The hospital
clinic is a suitable environment for such exercises. While no
other similar published reports could be found, the benefits of
medication review clinics in other specialities have been noted.
Morlidge (2001) reported upon the introduction of a renal
medication review clinic that showed similar benefits, such as
identification and withdrawal of unnecessary drugs, avoidance of
unnecessary repeat medication, improved concordance with
therapy, better drug history taking and reductions in wastage of
drugs and pharmacy time. Running the clinic alongside the
consultant clinic facilitated prompt liaison and ensured medica-
tion problems were promptly resolved. Austwick et al (2002)
reported the results of a study in palliative care, where drug
regimens can be as complex as those in cancer chemotherapy; it
was shown that the pharmacist’s input into the outpatient clinic
proved invaluable. In general, patients left the pharmacy clinic
with a better understanding of their medication as well as knowing
how to combat unpleasant side effects. Supply of medication was
more efficient, drug histories were kept up to date and medication
problems were better addressed.
Patient knowledge
After their initial diagnosis, breast cancer patients at Worthing
Hospital receive an explanation of their chemotherapy treatment
and its potential side effects from specialist nursing staff on
MDCU. Patients then receive their first cycle of chemotherapy after
which they are given their chemotherapy support medication with
a one-off explanation of how, when and why each item should be
taken. This study has shown that patients who attend the
pharmacy technician-led clinic had a significantly better level of
understanding of their chemotherapy support medication com-
pared to control patients receiving best standard care.
Pharmacy and nursing staff play key roles in educating patients
about their medicines; both are equipped with specialist knowl-
edge needed to relay important treatment information to patients.
Exploration of the factors that may have influenced the success of
the pharmacy technician-led clinic is worthwhile.
Chemotherapy is complex. The stigma surrounding cancer and
its treatment can understandably be very disheartening for
patients who after diagnosis, receive a plethora of important
Table 2 Main outcome measures to demonstrating the impact of the pharmacy-led clinic (clinic arm) compared to control
Feature
Control arm
n (%)
Clinic arm
n (%) Statistical inference
Primary outcome measure: patients’ understanding of their medication
Number of patients (n)6 9 6 9
Mean baseline score 2.942 2.922
Mean follow-up data score 2.965 5.417
Difference between mean baseline and follow-up scores (95%CI) 0.023 ( 0.228–0.182) 2.495 (2.165–2.826)
P 0.822 o0.001
Secondary outcome measures
Number of patients having chemotherapy delays 25 (36.2) 8 (11.6) w
2¼11.51, P¼0.001
Number of patients having chemotherapy dose reductions 21 (30.4) 7 (10.1) w
2¼8.78, P¼0.003
Total number of patients with drug interactions recorded 20 (28.6)
a 27 (39.1) w
2¼1.731, P¼0.188
Median number of items of support medication supplied per
patient per course
5
a 2 Po0.001, 95%CI¼1–3
Mean cost of items supplied per patient per course (+/  s.e.) d26.7 (+/ 4.7)
a d10.2 (+/ 1.5) t¼3.34, Po0.001
Number of patient prescriptions requiring intervention 32 (45.7) 21 (30.4) w
2¼3.439, P¼0.064
Mean time per patient spent resolving prescription issues (minutes) 9.9 1.8 Difference (95%CI)¼8.1 (5.05–11.04), Po0.001
aOne control subject was included at baseline, making n¼70 for this calculation.
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sinformation about their new (to them) condition. Some of this is
re-emphasised, often at the patient’s request, during the first
chemotherapy session on the ward. Apprehension and the
chemotherapy itself can often leave the patient feeling very tired
and confused. Anecdotally, patients at the pharmacy technician-
led clinic voiced the opinion that an environment away from the
ward was more relaxing and that in the ward environment, their
concentration had declined significantly before they received
information on their chemotherapy support medication. In
contrast, the pharmacy technician-led clinic provided an atmo-
sphere where they felt able to ask questions about their support
medication and absorb the information. The co-ordination of
pharmacy and nursing input may therefore be a crucial step in
improving this aspect of care.
Many different aides memoir or treatment prompts were
observed to be used by patients in this study. These ranged from
handwritten notes on the outer cartons to complete computer
spreadsheets allowing dose administration records to be kept.
Patients with more support medications relied heavily on these
treatment prompts and it was observed that in general, those
without prompts, particularly those taking larger numbers of
support medications, knew the least about their medications.
These patients scored poorly on the knowledge rating scale; this
was undoubtedly exacerbated by the fact that their mean score was
computed from a high number of treatments.
The scoring system used in this study was subjective but applied
consistently by one person (the chief investigator). Its application
in practice allowed simple rules to be used to assist consistency.
The scale was designed to allow weighting of parameters
depending on their importance to the patient’s understanding of
their treatment with more emphasis on drug name, indication and
frequency than strength and duration. Interestingly, the most
common information omitted by patients during interview was
indication and strength. These two pieces of information are very
useful, but for different reasons. While the former is obviously
important when the patient has to select the appropriate support
medication for symptom relief from a range of medicines, the
strength is of importance when supplying the information to a
healthcare professional so that a further supply or appropriate
substitute can be organised. The scale also demonstrated
consistency over time. In the control arm, there was little variation
in baseline and follow-up scores (see Table 2).
In general, patients tended to rate their level of understanding of
support medication higher than the investigator at both stages
of the study. This was the first question they were asked during
the interview. Following the assessment questions, many were
surprised at how little they knew. Self rating may have been lower
if the initial question had been asked at the end.
Whatever the patient’s initial level of understanding about their
support medication the study has demonstrated that the pharmacy
technician-led clinic produced significant improvements. Work
from a wide range of disciplines and clinical settings, indicates
that improved knowledge about their medications is linked to
improved patient concordance with therapy; although it seems
difficult to demonstrate beyond doubt. Horne (1998a) cites
evidence for a direct link between adherence to medication and
perceived symptomatic benefit; in our case, improved control of
the side effects of cancer chemotherapy. Clearly the pharmacy
technician-led clinic is an excellent opportunity to impart benefit
information.
Horne (1998b) undertook an extensive review of the literature
surrounding the factors affecting adherence. He found that
although a basic awareness of how and when to take medicines
was one pre-requisite for adherence it was insufficient on its own;
other factors such as the patient’s general health beliefs and
specific beliefs about medicines also played an important part;
furthermore, patients who were more satisfied with their care were
more likely to adhere to their treatment regimen. More specifically,
Craig and Powell (1987) observed that effective management of
chemotherapy-induced emesis improved overall patient adherence
and enhanced the effectiveness of patients’ chemotherapy. The
pharmacy technician-led clinic in our study provided the
opportunity for a full discussion on the support medication in
the context of the patient’s primary cancer chemotherapy, both in
terms of symptom recognition, choice of support medication and
clarification of dosage instructions. Patients were also given the
opportunity to ask questions about their management.
Breast cancer and its treatments involve many different facets
for the patient to get to grips with. Horne (1998b) has suggested
that in complex diseases, a patient who receives the information
over time in a variety of appropriate settings is likely to absorb
more and be a more concordant, happier and hopefully healthier
patient. A one-off session at the start of treatment is unlikely to be
as effective as successive encounters, where the patient can discuss
progress and have new enquiries dealt with (Horne, 2000). This
supports the repeat use of the pharmacy technician-led clinic on
each visit to the breast cancer clinic.
For most cancer patients, acceptance of chemotherapy is based
on the reality of a potentially terminal condition without it. Once
this initial step has been taken, information on how to modify the
debilitating effects of chemotherapy is fundamental to building a
successful concordant relationship based around the patient’s
needs. The healthcare team need to work on this concordant
relationship with the patient by providing excellent support that
engages in activities that maximise benefit from the patient’s
perspective.
It has been demonstrated that more active listening by
healthcare professionals is needed to avoid missing important
verbal and non-verbal signals that need to be followed up with the
patient (Blenkinsopp, 2001). The successful delivery of informa-
tion must include an interactive discussion with the patient. It has
been suggested that non-concordance may stem not from lack
of understanding but rather a conscious decision by a patient not
to take his/her medication as directed. The reasons for this are
undoubtedly multifactorial but must surely include the fear of
medication side effects. Once they have accepted their diagnosis
and the need for chemotherapy and have recognised the side
effects of the latter, cancer patients with a better understanding of
how those effects may be minimised with additional medicines
may be expected to concord with their support medication. This
decision might be reinforced by the knowledge that poor tolerance
of chemotherapy might lead to dose reductions, treatment delays
and possible disease progression or recurrence.
Whilst the association between the patient’s level of under-
standing and treatment concordance cannot be assumed from this
research, it is clear that the connection between the two concepts is
becoming increasingly important to understand.
This study highlighted that further work needs to carried out on
the association between level of patient understanding of therapy
and treatment concordance. This is particularly important where
the patient is being empowered to recognise the side effects of one
set of medications (the chemotherapy) and self-treat by selection
from a range of other medications (chemotherapy support
medication). At this stage, it is sufficient to conclude that
pharmacy input achieves greater understanding of these aspects
in breast cancer patients.
Chemotherapy delays and dose reductions
The pharmacy technician-led clinic produced significantly fewer
treatment delays and dose reductions in this study. In most cases,
delay was due to poor tolerance, which resulted in a dose
reduction. The most common reason for delay was uncontrolled
nausea and vomiting and there were notably more patients in the
control arm (17) compared to the clinic arm (6). This is one area
where the clinic appeared to be making an impact in terms of
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of appropriate antiemetic medication. Patients receiving adjuvant
therapy might be expected to suffer from nausea and vomiting to a
greater extent than patients receiving therapy for metastases and
there were more of the latter in the clinic arm of the trial. In some
cases, nausea and vomiting had been so severe that hospital
admission was necessary to allow resultant dehydration to be
resolved before administration of further chemotherapy. There
were also more patients on regimens with greater emtogenicity in
the clinic arm, notably FEC combinations (see Table 1).
More patients receiving trastuzumab monotherapy were rando-
mised into the control rather than the clinic arm of the trial (13 vs
two patients). Although this is a monoclonal antibody, emesis has
been observed in our clinics and indeed is featured in the
Summary of Product Characteristics. The Sussex Cancer Network
(referred to above) advises in its standard treatment proforma for
the drug that metoclopramide should be provided for all patients
and that treatment should be subject to the same scrutiny as other
drugs used in cancer chemotherapy. This was the case in our clinic
where all therapies requiring support medication were included.
Only one drug is recommended for support medication in this
case, compared to greater numbers for other chemotherapy
regimens encountered, reducing the potential for confusion. It is
likely that the imbalance of trastuzumab numbers would decrease
the impact of the pharmacy technician-led clinic rather than
enhancing it if the numbers were the other way round. The
imbalance is an artefact of strict randomisation.
Modern antiemetics, if used correctly, should result in fewer
cases of delayed nausea and vomiting, but if patients do not know
or cannot remember which ones to use and when, then their value
is compromised. The efficacy of other oral treatments that patients
may be taking may also be diminished due to impaired absorption
and consequent sub therapeutic levels; for example in our study
there were cases of neutropenic sepsis that may have been
prevented had the oral antibiotic patients were taking been
absorbed adequately. This study did not assess whether the
antibiotic had actually been taken or mistaken for another support
medication. A more in-depth study would be needed to determine
the contribution of non-compliance with support medication to
hospital admission of breast cancer patients for serious sequellae
such as these.
Drug interactions
Highlighting potential and existing drug interactions is an
important part of any patient – carer interaction and a primary
outcome of many studies of pharmacy and pharmacy technician
drug history taking conducted in hospital settings.
Due to the shared care agreement that currently exists for
oncology patients in the study area, drug histories are not taken
routinely for cancer patients; this study has highlighted the
difference the systematic taking of drug histories can make. Forty-
seven of the 139 patients who participated in the study had
potential drug interactions highlighted compared to none before
the study began.
Most potential drug interactions were reported between GP
prescribed medication and chemotherapy support medication
rather than chemotherapy itself. The majority of these involved
dexamethasone with NSAIDs, antidiabetic agents, anticonvulsants
and antihypertensive agents.
Chemotherapy support medication supplies
Effective medicines management is an important contributor to
the quality of healthcare, which provides patient-focussed care
based on need. In recent years, the Government has invested
millions of pounds in developing medicines management across
the NHS. Research has shown this strategy to produce financial
and other benefits such as improved quality of patient care, more
efficient dispensing, patient self-administration, medicines review
and continual patient education. It has been shown that the
concept of medicines management can be applied successfully to
most areas and intuitively, should be of particular benefit when
standard treatment regimens that require repeat dispensing are
used.
In this study, medicines management and medication review in
the pharmacy technician-led clinic reduced significantly the
number of support medications required. This in turn equated to
marked cost savings and a reduction in pharmacy dispensing time.
Prescription interventions
The nature of a shared care agreement between two NHS Trusts
does not always allow for efficient communication; for example in
this case, two discrete sites are involved and the oncologist
provides a visiting service from his base at one site to the other.
Prescription issues often occur during periods when it is most
difficult to resolve them quickly, for example when workload is
high and after busy outpatient clinics when the oncologist is
elsewhere. In this study, the pharmacy technician-led clinic led to a
significant reduction in pharmacy time spent resolving prescrip-
tion issues at the outpatient clinic.
In both study arms, the most common reported problem was
that additions to chemotherapy support medication were unclear
to staff. Clarification in the clinic when all healthcare team
members are present (oncologist, nurse, and pharmacy staff) is of
clear benefit to achieving the right patient prescription.
Overall costs of the scheme
Cost analysis of the scheme (see results above) indicates that the
initial, one-off payments for technician training (d1955.00) are
more than covered by a projected annual saving of d15706.67 in
terms of technician time saved (d1499.27) and reductions in
dispensing unnecessary medicines (d14207.4). Clearly the actual
annual amount will depend on patient throughput and complexity
of their regimens, but this result does provide another indication
that the approach is worthwhile.
CONCLUSION
This study has demonstrated that breast cancer patients at
Worthing Hospital had a significantly better understanding of their
chemotherapy support medication after attending the pharmacy
technician-led clinic compared to those patients who did not.
In addition, the study showed that for these patients there were
highly significant reductions in the number of chemotherapy
delays and dose reductions and the amount of repeat dispensing
of chemotherapy support medication, resulting in a significant
reduction in dispensary time and expenditure on medicines. There
was also a highly significant reduction in pharmacy time spent
resolving prescription issues at the point of dispensing.
We propose to extend the clinic to all breast cancer patients
at Worthing Hospital and investigate its application to other
specialities. A refinement to the process could include the
amalgamation of the initial nursing assessment of the patient with
the pharmacy technician-led clinic.
Chemotherapy support medications are commonly standard
treatments employed for standard regimens with standard
directions. Pre-labelled TTO packs could be available from the
pre-assessment clinic under a Patient Group Direction after the
pharmacy technician has taken a drug history and conducted a
medication review to establish what is required, thus saving
valuable dispensary time. The availability of a suitably qualified
and accredited pharmacist supplementary prescriber in the
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chemotherapy support medication could be provided in the clinic
without recourse to the dispensary. This is an attractive area for
future research.
This study showed that as well as providing a better under-
standing of drug treatments, pharmacy technician-led clinics are
also a prime opportunity to apply effective medicines management
and medication review.
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